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Abstract
Background: The pathogenesis of penile squamous cell carcinoma (PSCC) is not well understood, though risk factors
include human papillomavirus (HPV). Disruption of HER/PTEN/Akt pathway is present in many cancers; however there is
little information on its function in PSCC. We investigated HER family receptors and phosphatase and tension homolog
(PTEN) in HPV-positive and negative PSCC and its impact on Akt activation using immunohistochemistry and fluorescent in
situ hybridisation (FISH).
Methodology/Principal Findings: 148 PSCCs were microarrayed and immunostained for phosphorylated EGFR (pEGFR),
HER2, HER3, HER4, phosphorylated Akt (pAkt), Akt1 and PTEN proteins. EGFR and PTEN gene status were also evaluated
using FISH. HPV presence was assessed by PCR. pEGFR expression was detected significantly less frequently in HPV-positive
than HPV-negative tumours (p = 0.0143). Conversely, HER3 expression was significantly more common in HPV-positive cases
(p = 0.0128). HER4, pAkt, Akt and PTEN protein expression were not related to HPV. HER3 (p = 0.0054) and HER4 (p = 0.0002)
receptors significantly correlated with cytoplasmic Akt1 immunostaining. All three proteins positively correlated with
tumour grade (HER3, p = 0.0029; HER4, p = 0.0118; Akt1, p = 0.0001). pEGFR expression correlated with pAkt but not with
tumour grade or stage. There was no EGFR gene amplification. HER2 was not detected. PTEN protein expression was
reduced or absent in 62% of tumours but PTEN gene copy loss was present only in 4% of PSCCs.
Conclusions/Significance: EGFR, HER3 and HER4 but not HER2 are associated with penile carcinogenesis. HPV-negative
tumours tend to express significantly more pEGFR than HPV-positive cancers and this expression correlates with pAkt
protein, indicating EGFR as an upstream regulator of Akt signalling in PSCC. Conversely, HER3 expression is significantly
more common in HPV-positive cases and positively correlates with cytoplasmic Akt1 expression. HER4 and PTEN protein
expression are not related to HPV infection. Our results suggest that PSCC patients could benefit from therapies developed
to target HER receptors.
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Introduction
Penile carcinoma is rare in Europe and the USA, representing
0.3–0.5% of male malignancies. In the UK there are approxi-
mately 600 new cases each year, mostly after the sixth decade
[1,2]. The majority (95%) are penile squamous cell carcinomas
(PSCC) [3]. These may be divided into usual type (70%), highly
aggressive basaloid (10%) and a slow growing, low grade group of
‘verruciform’ tumours (20%) [4]. Mixed tumours of different
squamous cell carcinoma (SCC) subtypes also exist. The patho-
genesis of PSCC is not well understood. Common risk factors for
penile cancer include lack of circumcision during childhood,
phimosis, cigarette smoking [5] and HPV infection [3,6]. HPV
infection is present only in a subset of penile tumours [7].
Therefore, penile cancer may resemble vulvar carcinoma with two
aetiologies: one related to HPV and one unrelated. HPV related
carcinogenesis acts through disruption of RB/p16 and p21/p53
pathways [6,8]. However, little is known about HPV independent
carcinogenesis in penile SCC. A greater knowledge of the
mechanisms of the pathogenesis of HPV negative cancers may
assist in more tailored treatments as novel drugs now target
specific molecular pathways.
The HER/PTEN/Akt pathway is commonly disrupted in
cancer and treatment options targeting this pathway are widely
available [9]. The human epidermal growth factor receptor (HER)
family is composed of EGFR, HER2, HER3, and HER4
transmembrane tyrosine kinase receptors. Extracellular ligand
binding to HER receptors leads to their homo- or heterodimerisa-
tion, tyrosine phosphorylation and activation. Active receptors can
stimulate intracellular signalling pathways, including PI3K/Akt
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pathway, which regulates cell differentiation, migration, prolifer-
ation and survival. HER2 lacks a ligand-binding domain while
HER3 has impaired kinase function but they can compensate for
each others deficiencies and still generate potent signals through
heterodimerisation [10]. Overexpression of HER family proteins
has been linked to worse prognosis in several cancers. High
expression of EGFR has been reported in head and neck cancers,
gliomas and non-small cell lung cancers. This can be a result of
gene mutation, gene amplification or post-transcriptional changes.
HER2 is found amplified and overexpressed in 25% of breast
cancer [10], HER3 is overexpressed in breast, ovarian and
prostate cancers [11] but HER4 overexpression in some breast
and bladder cancers was correlated with better prognosis [12].
Activation of HER family by growth factors leads to activation
of phosphatidylinositol 3-kinase (PI3-kinase), which phosphory-
lates the membrane lipids phosphatidylinositol 4,5 bisphosphate
(PIP2) to phosphatidylinositol 3,4,5 triphosphate (PIP3). This
results in phosphorylation and activation of Akt. Akt is a serine-
threonine kinase. There are three isoforms of Akt in mammals:
Akt1, Akt2, Akt3, and their functions overlap but also show some
isoform specificity. Akt1 seems to play critical role in cell survival
and is overexpressed in high grade and stage carcinomas of
prostate, breast and ovary [13]. Akt2 is involved in the
maintenance of glucose homeostasis and Akt3 may play crucial
role in brain development [14]. Akt is present in the cytoplasm and
nucleus, where it promotes cell growth, proliferation and acts as an
anti-apoptotic agent. Akt targets include Bcl-2 family proteins, cell
cycle regulators such as p53, p21 and p27 and Fas ligand and
Forkhead transcription factors (FOXO) [15].
The Akt pathway is negatively regulated by phosphatase and
tension homolog (PTEN). PTEN has both lipid and protein
phosphatase activity. It antagonises PI3 kinase by de-phosphory-
lating PIP3 in the cytoplasm to PIP2. PTEN is often inactivated
and downregulated in cancer, including skin SCC [16], which
results in constitutive activation of the PI3K/Akt pathway [17].
There is very limited data available on the HER/PTEN/Akt
pathway in PSCC and its possible involvement in carcinogenesis.
Studies on small series of penile cancer show frequent overex-
pression of EGFR, but there is no data on other HER receptors in
penile cancer [18,19]. One study by Andersson et al [20]
investigated the mutational status of PIK3CA and PTEN genes in
PSCC but not protein expression. Therefore, we decided to
investigate the role of this pathway in PSCC more fully, including
all members of HER family, PTEN and Akt status and EGFR and
PTEN gene copy number, using immunohistochemistry and
fluorescent in situ hybridisation methods. We also correlated the
results to HPV status, which we previously assessed for this patient
cohort [8] with the hypothesis that HPV negative tumours may
show different activations of this pathway than HPV positive
tumours. Our study confirmed that there is a difference in HER
family involvement in HPV related and unrelated penile tumours.
Materials and Methods
All human penile cancer samples used in this study were
archival material obtained without written consent from Cellular
Pathology Department Registry of St George’s Hospital and were
analyzed anonymously. The study was approved by East London
and The City Research Ethics Committee. We retrieved 148
samples of which 97 were usual type PSCCs, 17 basaloid, 15 pure
verrucous carcinomas, 7 mixed verrucous/usual type, 7 mixed
verrucous/warty, 2 warty and 3 warty/usual types. 21 cases were
obtained from excision biopsies/circumcisions, 82 from glansec-
tomies and 45 from partial/total penectomies. All cases were re-
reviewed by an expert uropathologist (C.C.) including subtyping,
grading and staging by standard methodologies [4,21].
Immunohistochemistry
Tissue microarray blocks were prepared using a manual
microarrayer. Three x 1 mm tissue cores were taken from each
tumour. Four mm sections were cut and immunostained using
standard heat-induced antigen retrieval methods (pressure cooking
for 10 min) with citrate buffer, pH 6.0 and the ABC kit (Vector
Laboratories, PK-6200) [22]. For phospho-EGFR (pEGFR)
microwaving in 1 mM EDTA buffer, pH 8.0 for 15 min was
used, according to manufacturer instructions. Primary antibodies
were applied as follow: pEGFR (Tyr845), 1:400 (Cell Signaling,
2231); HER2 (clone 10A7), 1:80 (Novocastra, NCL-CBE-356);
HER3 (clone RTJ1), 1:100 (Novocastra, NCL-c-erbB-3); HER4
(clone sc-283), 1:500 (Santa Cruz, ErbB-4); Akt1 (clone 2H10),
1:500 (Cell Signaling, 2967); phospho-Akt (pAkt, Ser473), 1:75
(Cell Signaling, 4051); PTEN (clone 28H6), 1:150 (Novocastra,
NCL-PTEN). Positive controls included placenta (pEGFR), breast
carcinoma (HER2, HER4), normal kidney (HER3), prostate
carcinoma (pAkt, Akt1) and normal tonsil (PTEN). For negative
control slides, primary antibody step was omitted and only
antibody diluent applied instead. Sections were scored semi-
quantitatively by a consultant genitourinary pathologist (D.B.). All
HER receptors showed membranous staining. HER3 and HER4
displayed also cytoplasmic positivity. For scoring purposes only
membranous staining was considered as positive [23]. Akt1 and
pAkt showed nuclear and cytoplasmic staining. The intensity of
staining was measured as 0 (no staining), 1 (weak), 2 (medium) and
3 (strong). For nuclear positivity of pAkt and Akt1 each core was
additionally given an estimated visual score between 0–100%,
representing the percentage of positively stained neoplastic nuclei.
The final score was then deduced by multiplying the percentage of
staining by intensity to give an expression score from 0–300. The
core with highest score was selected for analysis. Statistical analysis
was performed using StatsDirect software, version 2.60.6000. The
correlations between antibodies were evaluated using Spearman’s
rank correlation test and their relation to tumour grade and stage
by Chi-Square test or Fisher’s exact test. The cut-off points
selected for antibody positivity were: $2 for pEGFR, HER2,
HER3, HER4 [24] and PTEN (intensity as seen in normal
surrounding tissue = 2 or stronger = 3) [25] and .0 for Akt1 and
pAkt [26]. All analyses were 2-sided, p,0.05 was considered to be
significant.
Fluorescent in situ hybridisation
For amplification of EGFR and PTEN gene deletion we used
commercial FISH probes from Abbott Molecular (Maidenhead,
UK): the LSI EGFR (7p12)/CEP 7 Dual Color Probe and the LSI
PTEN (10q23)/CEP 10 Dual Color Probe [27,28]. Both gene
probes were labeled SpectrumOrange and control centromere
probes SpectrumGreen.
TMA slides were dewaxed in xylene, washed in ethanol and
water. Next, they were boiled in pre-treatment buffer (Spotlight
tissue pre-treatment kit, Invitrogen) for 15 minutes and digested
with pepsin solution (Digest All-3, Invitrogen) for 5 minutes at
28uC. After washing in water and air-drying the slides, the probe
was applied following the manufacturer instructions and slides
were denatured at 95uC for 10 minutes. The slides were then
hybridised at 37uC for 24 hours. A post-hybridization wash in 0.5
x SCC buffer for 5 min at 37uC was performed, followed by PBS
washes. Slides were then dried, counterstained and mounted with
Vectashield antifade solution containing DAPI (Vector Laborato-
ries LTD).
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FISH slides were scanned and analysed using the Applied
Imaging AriolH System (Applied Imaging, San Jose, CA, USA). A
minimum of 100 cells with clear hybridization signals were
counted per core using the centromere signal as an internal control
[28]. On the basis of FISH results in normal penile foreskin,
tumours with more green FISH signal (centromere) in .10% of
cells were considered positive for gene copy number loss while
tumours with more red FISH signal (EGFR or PTEN gene) in
.10% of cells were considered positive for gene copy number
gain. No signal clusters specific for gene amplification were
present.
Due to typical variation in cutting TMA blocks, some cores
were not seen on the stained sections or had not enough cancer
tissue left in them for proper assessment. Therefore, number of
patients for each antibody/probe is different.
Results
Immunohistochemistry
Examples of immunostaining are shown in Figure 1. Proteins
immunoexpression in relation to tumour grade and stage is shown
in Table 1. pEGFR protein (Figure 1A) was present in 25% (36/
144) of penile SCCs and showed a non-significant trend to be
more positive in early stage tumours (p = 0.0686). All tumours
were negative for HER2. HER3 was widely expressed (Figure 1B)
with membranous staining present in 86% (120/139) of tumours.
Membranous HER4 was detected in 18% (22/125) of PSCCs
(Figure 1C). Membranous HER3 and HER4 showed strong
positive correlations with histological grade (p = 0.0029 and
0.0118, respectively). None of the HER receptors significantly
correlated with tumour stage. Nuclear Akt1 staining was present in
52% (76/147) of cancers. Cytoplasmic Akt1 (Figure 1D) was
positive in 37% (54/147) of penile cancers and it strongly
correlated with tumour grade (p= 0.0001). pAkt (Figure 1E)
showed nuclear positivity in 42% (59/141) of cancers and cyto-
plasmic staining in 68% (96/142). There was a strong negative
correlation of nuclear pAkt with tumour stage (p = 0.0016). Lost or
reduced PTEN immunoexpression (Figure 1F) was present in 62%
(84/135) of our patients and it weakly but significantly positively
correlated with tumour grade (p = 0.0403).
PTEN protein negatively correlated with pEGFR (0.0474) but
also at borderline levels of significance. Cytoplasmic Akt1 strongly
significantly correlated with HER3 (0.0054), HER4 (0.0002) and
pAkt proteins (nuclear, p = 0.0107 and cytoplasmic, p = 0.0239).
pEGFR highly significantly correlated with nuclear (p,0.0001)
and cytoplasmic (p = 0.0002) pAkt protein.
Figure 1. Immunoexpression of pEGFR, HER3, HER4, pAkt, Akt1 and PTEN proteins in PSCC. Strong immunoexpression of pEGFR (A),
HER3 (B) and HER4 (C). pAkt (D) and Akt1 (E) show both nuclear and cytoplasmic staining. PTEN expression is restricted to nuclei only and reduced
staining was often found in cancer cells (F). Scale bar: 50 mm.
doi:10.1371/journal.pone.0017517.g001
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Fluorescent in situ hybridisation
There was no EGFR gene amplification in penile SCC
(Figure 2A). EGFR gene copy number gain was detected in 14%
(19/140) of tumours and in 12 of them was present only in 11–
20% of cells. There was no correlation between EGFR gene copy
number and protein expression.
PTEN gene copy number loss was infrequent in penile cancer
and present as heterozygous deletion in 5/129 (4%) of tumours
(Figure 2B). Three of those cases expressed PTEN protein with
medium intensity. There were no cases of homozygous deletion.
HPV data
In our previous study we tested 102 penile SCC from the same
cohort for the presence of HPV DNA by a broad-spectrum HPV
PCR method using SPF10 primers [8]. Briefly, HPV DNA was
detected in 57/102 (56%) of PSCCs. High-risk type 16 was the
Table 1. Antibody detection of expressed proteins in correlation with grade and stage of penile tumours.
Ab1 type Grade Ab positive (%) Ab negative (%) p value Stage Ab positive (%) Ab negative (%) p value
pEGFR2 1 10 (31) 23 (69) 0.1111 1 17 (35) 32 (65) 0.0686
2 18 (40) 27 (60) 2 17 (25) 52 (75)
3 8 (15) 45 (85) 3+4 2 (9) 20 (91)
HER3 m3 1 21 (68) 10 (32) 0.0029 1 35 (78) 10 (22) 0.0615
2 54 (95) 3 (5) 2 64 (93) 5 (7)
3 45 (88) 6 (12) 3+4 18 (86) 3 (14)
HER4 m 1 0 (0) 26 (100) 0.0118 1 8 (20) 32 (80) 0.7605
2 12 (23) 40 (77) 2 11 (17) 52 (83)
3 10 (21) 37 (79) 3+4 2 (11) 16 (89)
pAktn4 1 14 (45) 17 (55) 0.6961 1 28 (62) 17 (38) 0.0016
2 21 (38) 35 (62) 2 20 (29) 49 (71)
3 24 (44) 30 (56) 3+4 8 (35) 15 (65)
pAktcyt5 1 24 (75) 8 (25) 0.5138 1 32 (71) 13 (29) 0.231
2 38 (68) 18 (32) 2 49 (70) 21 (30)
3 34 (63) 20 (37) 3+4 12 (52) 11 (48)
Akt1n 1 13 (37) 22 (63) 0.0951 1 25 (51) 24 (49) 0.6783
2 35 (60) 23 (40) 2 35 (51) 34 (49)
3 28 (52) 26 (48) 3+4 14 (61) 9 (39)
Akt1cyt 1 3 (9) 32 (91) 0.0001 1 19 (30) 30 (61) 0.9363
2 26 (45) 32 (65) 2 25 (36) 44 (64)
3 25 (46) 29 (54) 3+4 8 (35) 15 (65)
PTEN 1 14 (47) 16 (53) 0.0403 1 13 (30) 30 (70) 0.4467
2 25 (45) 30 (55) 2 29 (42) 40 (58)
3 12 (24) 38 (76) 3+4 8 (40) 12 (60)
1Ab, antibody.
2p, phosphorylated, active protein.
3m, membranous expression.
4n, nuclear expression.
5cyt, cytoplasmic expression.
doi:10.1371/journal.pone.0017517.t001
Figure 2. EGFR and PTEN copy number status using fluorescent in situ hybridisation. EGFR gene copy number gain (arrows) but no
amplification signal clusters are present in some tumours (A). PTEN gene copy number loss (arrows) is present in a small fraction of tumour cells (B).
doi:10.1371/journal.pone.0017517.g002
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most prevalent type, present in 46/57 (81%) of HPV positive
tumours. The HPV data was used to assess the possible differences
in the proteins immunoexpression between HPV-positive and
negative tumours (Table 2). Comparison between HPV-positive
and negative cases showed significant difference in membranous
HER3 expression, with more HER3 positivity in HPV-infected
tumours (53/56 (95%) vs 30/40 (75%), p = 0.0128). pEGFR
protein was detected significantly less frequently in HPV-positive
tumours when compared to HPV negative tumours (9/57 (16%) vs
17/43 (40%), p = 0.0143). EGFR gene copy gain was present in
11/91 (12%) of cases tested for HPV, regardless of HPV infection.
HER4, pAkt, Akt and PTEN protein immunoexpression were not
significantly different in HPV-positive and negative samples. HPV
status was known for 4 of 5 cases with heterozygous deletion of
PTEN. Three tumours were positive for HPV infection.
Discussion
The pathogenesis of penile cancer is not well understood. A
substantial percentage of penile carcinomas are associated with
HPV while the remaining tumours rely on molecular mechanisms
other than HPV [3,6]. We previously assessed HPV status in 102
samples from this series and found HPV DNA present in 56%
(57/102) of cases [8], which is similar to previous reports [7,29].
We also confirmed that HPV infection leads to deregulation of
RB/p16 and p21/p53 pathways visible in overexpression of p16
and p21 and downregulation of RB protein [8]. In the current
project we concentrated on investigating the HER/Akt/PTEN
pathway, comparing our results to HPV status in those tumours in
order to assess a possible influence of HPV on function of this
pathway.
Studies in cell culture models show that HPV16 E5 protein
upregulates EGFR-mediated signal transduction, partially through
decreased downregulation and recycling of activated receptor to
the plasma membrane [30]. Interestingly, we observed signifi-
cantly lower pEGFR immunoexpression in HPV-positive than
HPV-negative tumours (p = 0.0143) which contradicts the cell
culture model hypotheses and suggests a greater role of EGFR in
HPV independent penile carcinogenesis. Similar results were
previously reported in HPV-related head and neck cancers
[31,32]; however, the mechanism of this relation is not clear.
Mayer et al [33] also reported decreased EGFR expression in
cervical SCC when compared to low grade dysplastic tissue.
Cervical cancer is strongly related to HPV infection and
integration of HPV DNA into host genome is frequently seen in
invasive cervical carcinomas and in a subset of CIN3. As the
integration process disrupts most of viral genes, sparing only E6
and E7, they suggested that the E5-related increase in EGFR
expression could be lost in cancer due to the integration process
resulting in abrogation of E5 expression [34]. It is possible that
HPV-positive penile cancers, similar to cervical tumours, rely on
E5 dependent, EGFR-driven cell proliferation only in the early
stages of the disease. After HPV integration they sustain cell
proliferation in EGFR independent fashion, e.g. through disrup-
tion of RB/p16 pathway by E6/E7 oncoproteins.
In our study we concentrated on the expression of phosphor-
ylated, active EGFR protein as the assessment of active protein
(rather than total protein) or gene amplification status seems to be
more valuable in terms of patient selection for anti-EGFR cancer
therapy and their response to treatment [35,36]. Two recent
studies reported very high expression of EGFR protein (91–100%)
in relatively small series of penile SCC and its lack of correlation
with histological grade, stage or survival [18,19]. pEGFR was
present only in 25% (36/144) of our PSCCs. FISH revealed a lack
of EGFR gene amplification. Gene copy number gain was
independent of tumour HPV status and present in 14% (19/
140) of cases with no detectable impact on phosphorylated EGFR
protein immunoexpression [36]. Activated EGFR is significantly
associated with phosphorylated nuclear and cytoplasmic Akt,
indicating that EGFR is an upstream regulator of PI3K-Akt
signalling in penile cancer. However, a lack of association with
Akt1 suggests that EGFR may activate other Akt isoforms.
Additionally, pEGFR showed an inverse correlation with PTEN
protein expression (p = 0.0474), which is in agreement with recent
findings that PTEN accelerates downregulation of activated
EGFR [37].
We did not detect HER2 protein in PSCC, which implies a lack
of involvement of this receptor in penile carcinogenesis. HER3 on
the contrary was widely expressed and present in 86% (120/139)
of tumours while membranous staining of HER4 was present in
18% (22/125) of cases. HER3 protein (p = 0.0128) but not HER4
(p = 0.3348) was significantly more common in HPV-positive
cancers. It is likely that in penile cancer HPV could upregulate
HER3 protein expression, possibly through its viral E6 and/or E7
Table 2. Specific antibody detection of expressed proteins in penile tumours with known HPV status.
Type of antibody Positive antibody detection (%)
All tumours HPV-positive tumours HPV-negative tumours P value
pEGFR1 26/100 (26) 9/57 (16) 17/43 (40) 0.0143
HER3 m2 83/96 (86) 53/56 (95) 30/40 (75) 0.0128
HER4 m 11/85 (13) 8/48 (17) 3/37 (8) 0.3348
pAktn3 47/98 (48) 30/57 (53) 17/41 (42) 0.3752
pAktcyt4 68/100 (68) 38/57 (67) 30/43 (70) 0.9104
Akt1n 56/101 (55) 29/57 (51) 27/44 (62) 0.3956
Akt1cyt 40/101 (40) 25/57 (44) 15/44 (34) 0.4294
PTEN 37/94 (39) 23/54 (43) 14/40 (35) 0.5951
P values show difference between HPV-positive and negative tumours.
1p, phosphorylated, active protein.
2m, membranous expression.
3n, nuclear expression.
4cyt, cytoplasmic expression.
doi:10.1371/journal.pone.0017517.t002
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oncoproteins as it does with HER2 protein in human cervical
keratinocytes [38]. Further studies are necessary to understand
HER3 involvement in HPV-related penile carcinogenesis.
HER3 immunostaining strongly positively correlated with
cytoplasmic Akt1 expression (p= 0.0054), suggesting that HER3
is an upstream regulator of the Akt1 pathway. HER3 is well
known as the most potent activator of the PI3K/Akt pathway.
However, it does not have an intrinsic kinase activity, and has to
relay on a heterodimeric partnership with other HER family
members for signal transduction. In penile cancer, it may form
heterodimers with the HER4 receptor, as both receptors
frequently co-expressed in our series. They both were also
positively associated with cytoplasmic Akt1 expression (p= 0.054
for HER3 and p= 0.0002 for HER4) and increased tumour grade
(Table 1). Similar receptors co-expression has been previously
described in cervical cancer [39]. However, membranous
expression of HER4 was much less common in penile cancer
than HER3 and detected only in 18% (22/125) of cases.
Therefore, other mechanisms than HER heterodimerisation must
be involved in HER3 activation in PSCC. In other cancer models
HER3 is known to be activated without apparent involvement of
the other HER family members and may be transactivated by
cellular stress and cytokines, including tumour necrosis factor a
and interferon a [11].
pAkt and Akt1 immunoexpression did not correlate with HPV
in our penile cancer series. This is not surprising since activation of
all HER proteins, regardless of their relation to HPV can lead to
Akt overexpression. Various tumours overexpress different Akt
isoforms implying that relative importance of the isoforms is
cancer specific [14,40]. Additionally, the function of Akt kinase
depends on its cellular localisation. While nuclear functions of Akt
are not well understood, cytoplasmic Akt is well known to be
involved in anti-apoptotic and pro-proliferative activities in human
cancer [41]. Interestingly, in our study both receptors HER3 and
HER4 associated with cytoplasmic expression of Akt1. Moreover,
they all significantly positively correlated with tumour grade,
suggesting that Akt1 pathway might be involved in tumour
progression. However, additional studies involving the other two
Akt isoforms are necessary to confirm this hypothesis. The critical
role of Akt1 in cell survival was also found in high grade and stage
carcinomas of prostate, breast and ovary [13].
The Akt pathway can be activated through inactivation and
downregulation of its negative regulator, PTEN [17]. PTEN
downregulation has been previously indicated in carcinogenesis of
skin SCC [16]. Loss of heterozygosity on chromosome 10q, where
PTEN gene is located has been reported in over 25% of human
skin SCCs [42]. Lost or reduced PTEN immunoexpression was
present in 62% (84/135) of our patients regardless of HPV status
and it positively correlated with tumour grade (p = 0.0403).
Diminished PTEN protein immunoexpression was not caused by
gene copy number loss as FISH analysis revealed heterozygous
deletion of PTEN gene only in 4% (5/129) of tumours.
Furthermore, loss of PTEN did not correlate with increased
phosphorylated Akt expression, indicating that other factors; e.g.
overexpressed HER3 and HER4 proteins may have greater
impact on increased activation of PI3K/Akt pathway in penile
cancer.
These results suggest that penile cancer patients with surgically
incurable disease may benefit from anti-cancer therapies devel-
oped to target HER receptors. Anti-EGFR therapies such as
monoclonal antibodies (cetuximab) or small molecule tyrosine
kinase inhibitors (TKI) (erlotinib, gefitinib and lapatinib) [43]
could be employed particularly to treat HPV-negative penile
tumours. Tyrosine kinase inhibitors (TKI) are known to effectively
prevent autophosphorylation of EGFR and HER2. However,
HER3 is kinase inactive and is not a direct target of the TKIs.
Consequently, through heterodimerisation with other receptors,
HER3 eventually leads to drug resistance and is responsible for
driving PI3K/Akt signalling in those cancers [10]. Therefore,
better treatment options need to be developed to efficiently treat
HER3-overexpressing cancers, including PSCC. Anti-cancer
therapy targets downstream of the HER3 pathway, such as
PI3K or Akt proteins may be more helpful in inhibiting Akt
signalling. Research is being conducted in search of potent PI3K/
Akt inhibitors, learning from studies on the PI3K inhibitors:
LY294002 and wortmannin [44]. In view of the very small
numbers of penile cancers and consequent lack of support for
clinical trials, practical approaches to likely therapeutic targets in
selected cases may be the best option for this rare but debilitating
disease.
Conclusions
EGFR, HER3 and HER4 but not HER2 are associated with
penile carcinogenesis. There is a difference in HER family protein
immunoexpression in HPV related and unrelated penile tumours.
HPV-negative tumours tend to express significantly more
activated EGFR than HPV-positive cancers and this expression
correlates with activated Akt protein, indicating EGFR as an
upstream regulator of Akt signalling in penile cancer. Conversely,
HER3 expression is significantly more common in HPV-positive
cases and positively correlates with cytoplasmic Akt1 expression.
HER4 expression is independent of HPV, but similar to HER3 it
positively associates with cytoplasmic Akt1 protein suggesting their
involvement in the Akt1 signalling pathway. Loss of PTEN protein
expression, unrelated to its gene copy status, is also not related to
HPV infection and does not visibly affect phosphorylated Akt
protein expression. Our results suggest that penile cancer patients
could benefit from anti-cancer therapies developed to target HER
receptors. However, further studies are needed to confirm HER
family involvement in penile carcinogenesis.
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